肿瘤溶解病毒的使用已成为临床上治疗各种肿瘤类型的吸引人工具。这类病毒经基因改造，可以在恶性细胞中有条件地复制，而对健康细胞无害。这种平台具有高度特异性的肿瘤杀伤效果，并具有出色的安全性。然而，仅作为肿瘤溶解平台使用的病毒在小鼠模型和临床中的肿瘤清除中并没有产生有效果。实际上，抗肿瘤免疫应答的产生占据了肿瘤溶解病毒的大部分抗肿瘤效应的原因。在本综述中，我们将讨论科学家们采用的各种策略，以增强由肿瘤溶解病毒驱动的抗肿瘤免疫应答。此外，还将重点探讨通过添加肿瘤相关肽来个性化这种抗肿瘤应答。

The use of oncolytic viruses has become an attractive tool in the clinics for the treatment of various tumor types. Such viruses are genetically modified to conditionally replicate in malignant cells while unharming healthy cells. This platforms offers a highly specific tumor killing with exceptional safety profiles. However, the use of oncolytic viruses as sole oncolytic platforms have rendered ineffective in tumor clearance in both murine models and in the clinics. In fact, the formation of anti-tumor immune responses attributes to most of the anti-tumor effects of oncolytic viruses. In this review we will discuss the various strategies scientists have employed to enhance the anti-tumor immune responses driven by oncolytic viruses. Moreover, a focus will be drawn into personalizing such anti-tumor responses by the addition of tumor associated peptides.